From the source
Google DeepMind has announced AlphaGenome 2, a DNA sequence model that predicts how genetic variants affect specific human cell types, giving scientists a way to find the cellular drivers of disease.
- The first AlphaGenome predicted molecular activity across broad tissues, which spread the model's capacity thin and made subtle differences between closely related cell types hard to capture.
- AlphaGenome 2 is a conditional model: it takes a tissue, cell type or state alongside a million-letter DNA sequence and uses that condition at every stage of its architecture.
- DeepMind says it identifies nearly twice as many variants that change gene expression in cells as the previous state-of-the-art model, and on the TenK10K dataset of 28 primary immune cell types it identified 30% of causal variants against 16% for the original AlphaGenome fine-tuned on single-cell data.
- The model was trained on more than 107 million individual cell profiles from human and mouse samples across 68 tissues, and it adds DNA methylation to the readouts the original model predicted.
- AlphaGenome 2 is available today for non-commercial research through the AlphaGenome API, and in private preview for commercial research.





